BridgeBio Pharma Shares Outstanding 2018-2024 | BBIO
BridgeBio Pharma shares outstanding from 2018 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
BridgeBio Pharma Annual Shares Outstanding
(Millions of Shares) |
| 2023 |
163 |
| 2022 |
147 |
| 2021 |
144 |
| 2020 |
118 |
| 2019 |
105 |
| 2018 |
62 |
| 2017 |
31 |
BridgeBio Pharma Quarterly Shares Outstanding
(Millions of Shares) |
| 2024-09-30 |
189 |
| 2024-06-30 |
188 |
| 2024-03-31 |
179 |
| 2023-12-31 |
163 |
| 2023-09-30 |
163 |
| 2023-06-30 |
161 |
| 2023-03-31 |
153 |
| 2022-12-31 |
147 |
| 2022-09-30 |
148 |
| 2022-06-30 |
147 |
| 2022-03-31 |
146 |
| 2021-12-31 |
144 |
| 2021-09-30 |
147 |
| 2021-06-30 |
147 |
| 2021-03-31 |
139 |
| 2020-12-31 |
118 |
| 2020-09-30 |
118 |
| 2020-06-30 |
117 |
| 2020-03-31 |
118 |
| 2019-12-31 |
105 |
| 2019-09-30 |
117 |
| 2019-06-30 |
93 |
| 2019-03-31 |
92 |
| 2018-12-31 |
|
| 2018-09-30 |
61 |
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.260B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
